INTRODUCTION
Bronchial asthma is a syndrome characterized by episodes of variable obstruction of airway, largely reversible either spontaneously or with treatment. 1 Asthma affects an estimated 300 million individuals worldwide. Annually, the World Health Organization (WHO) has estimated that 15 million disability adjusted life years are lost and 250,000 asthma deaths are reported worldwide. 2 Fluticasone is a potent ICS with a well-established efficacy and safety profile. It blocks the late-phase allergen in the response in the lung and decreases airway hyper responsiveness. 3, 4 It is rapidly absorbed from the lungs into the systemic circulation, with a half-life of 7.8 hours. Systemic bioavailability is approximately 17%. 5, 6 while formoterol and salmeterol are LABA. Formoterol has a rapid onset of action of between 1 and 3 min but both have sustained, dose-dependent bronchodilator effects.
The present study was undertaken to compare the efficacy of ICS/LABA fixed maintenance-dose treatment with formoterol/fluticasone and salmeterol/fluticasone for maintenance and rescue therapy in patients with asthma aged ≥18 years. Study also evaluated the tolerability of a new asthma therapy with combination administered twice daily (b.i.d.) via MDI in adult and adolescent patients with moderate asthma.
METHODS
The present study was an open label, parallel, prospective, randomized, comparative and interventional study of 8 weeks duration, was conducted in the Department of Pharmacology in collaboration with Department of Tuberculosis and Chest Diseases, Government Medical College, Amritsar. Total 80 patients of bronchial asthma of either sex with age 18 to 60 years were enrolled in the study. Spirometry was done by using Spiro meter SpiroExcel by MEDICAID. It's a Digital Spirometer with automatic interpretation by assessment of various parameters viz FVC, FEV1, FEV1/FVC, PEFR. After assessment, patients were randomly divided in two groups A and B, comprising of 40 patients each. Each patient was educated and trained for correct use of Metered dose inhaler (MDI).
• Group A patients were treated 2 actuations of Fluticasone + Formoterol (6/125µg) using MDI with the interval of 5 minutes, twice daily.
• Group B patients were treated with 2 actuations of Fluticasone + Salmeterol (50/125µg) using MDI with the interval of 5 minutes, twice daily.
For patients using either drug who still suffer acute exacerbations were permitted to take salbutamol (2 actuation of 100µg each) up to 4 occasions per day as reliever medication by Metered dose inhaler. Patients were asked to swish and gargle with water to minimize the chances of oropharyngeal candidiasis.
The approval of ethics committee was taken before the start of study. The patients who met the inclusion criteria were recruited in study after informing the patients regarding the study in their vernacular language and taking written informed consent.
Inclusion criteria
• Age 18-60 years of either sex • Newly diagnosed patients with bronchial asthma • Partly controlled asthma (according to GINA guidelines)
Bronchodilator reversibility >12% and 200ml of FEV1 after salbutamol inhalation (2 actuations, 100µg per actuation) (according to GINA guidelines).
Exclusion criteria
• Life threatening asthma within past year • Hospitalization/Emergency department visit in 4weeks prior to screening • Systemic corticosteroid used in 1 month prior to screening Total 80 patients were enrolled in the study randomly divided into two groups -group A (n=40) and group B (n=40). Baseline characteristics like demographic profile and hematological parameters, observed in patients of both the groups during the study period as given in the Table 1 .
All the values at each follow up were significantly better than baseline in both groups but statistically nonsignificant difference observed between the two groups at each follow up (Table 2) . All the values at each follow up were significantly better than baseline in both groups but statistically nonsignificant difference observed between the two groups at each follow up (Table 3 ).
All the values at each follow up were significantly better than baseline in both groups but statistically nonsignificant difference observed between the two groups at each follow up (Table 4) . All the values at each follow up were significantly better than baseline in both groups but statistically nonsignificant difference observed between the two groups at each follow up (Table 5 ). (Table 6 ).
Mean number of rescue doses and night awakening events were reduced with treatment in both the groups from 4 weeks to 8 weeks, but the difference between the two groups were statistically non-significant (p >0.05).
Figure 1: Comparison of adverse drug reactions.
During the study period, there was no serious adverse drug reaction observed in both the groups. Group B patients had comparatively more anxiety and restlessness whereas tachycardia was more common in group A. But all gets improved gradually and both the drugs were well tolerated over the 8-week study period.
DISCUSSION
In group A, there were 19 (47.5%) females and 21 (52.5%) males and group B, there were 18 (45%) females and 22 (55%) males. Mean age for group A was 39.4 years and that for group B was 38.7 years. Hence, groups A and B were comparable at baseline as the difference between age and sex were statistically non-significant (p-value 0.791 and 1.0 respectively) ( Table 1) .
Common symptoms reported in this study were chest tightness/breathlessness with cough and wheezing which were improved significantly with the treatment in patients of both groups. Need for rescue doses with salbutamol and number of night awakenings also decreased in both the groups (Table 7) which is in consistence with previous study. 7 Tachycardia was more commonly observed in patients of group A, whereas restlessness, anxiety and insomnia were mostly seen in patients of group B than group A but these are statistically non-significant [(p >0.05) Figure 1] . But all the side effects improved gradually and tolerance developed over the 8-week study period, with no serious drug-related adverse events.
Both the combinations of fluticasone with formoterol and salmeterol were effective in significantly improving pulmonary function tests -FVC, FEV1, FEV1/FVC and PEFR at both follow-up visits.
Group A (Fluticasone and Formoterol)
In Group A patients, mean of percent predicted FEV1 improved from baseline to 8 weeks was found to be 11.94% and is statistically significant (p <0.001). Percent at baseline predicted values of FVC and PEFR were 3.76% and 3.17% respectively at 8 weeks compared to baseline, which is statistically significant (p <0.001). Mean percent improvement in FEV1/FVC at 8 weeks from baseline was 7.14%, which is statistically significant (p <0.001) ( Table  6 ). Similar improvement in pulmonary function tests on treatment with fluticasone and formoterol was observed in previously done studies.
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Group B (Fluticasone and Salmeterol)
In Group B patients, mean percent improvement in FEV1 from baseline to 8 weeks was found to be 8.82% and is statistically significant (p <0.001). mean percent improvement in FVC and PEFR were 3.75% and 3% respectively at 8 weeks compared to baseline, which is statistically significant (p <0.001). Mean percent improvement in FEV1/FVC at 8 weeks from baseline was 7.14%, which is statistically significant (p <0.001) ( Table  6 ). Similar improvement was observed in pulmonary function test parameters on treatment with fluticasone and salmeterol in previously done studies.
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Group A versus Group B
FVC
Mean change in FVC at 4 weeks and 8 weeks in group A was higher than mean change in FVC in group B patients. But result found to be statistically non-significant (p > 0.05) ( Table 3) .
FEV1
Mean change in FEV1 at 4 weeks and 8 weeks in group A was higher than mean change in FEV1 in group B patients. But result found to be statistically non-significant (p > 0.05) ( Table 2) .
PEFR
Mean change in PEFR at 4 weeks and 8 weeks in group A was higher than mean change in PEFR in group B patients. But result found to be statistically non-significant (p > 0.05) ( Table 5) .
FEV1/FVC
Mean change in FEV1/FVC at 4 weeks and 8 weeks in group A was higher than mean change in FEV1/FVC in group B patients. But result found to be statistically nonsignificant (p > 0.05) ( Table 4) .
Comparison between the two groups on the basis of improvement in pulmonary function tests (FVC, FEV1, PEFR and FEV1/FVC) demonstrated no significant change at the end of the study period as depicted in previous studies. 7, 10 
